Literature DB >> 28464003

Towards control of the global HIV epidemic: Addressing the middle-90 challenge in the UNAIDS 90-90-90 target.

Collins Iwuji1,2, Marie-Louise Newell3.   

Abstract

In a Perspective, Collins Iwuji and Marie-Louise Newell discuss early findings from Richard Hayes and colleagues' PopART study on HIV testing and treatment.

Entities:  

Mesh:

Year:  2017        PMID: 28464003      PMCID: PMC5412986          DOI: 10.1371/journal.pmed.1002293

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.069


In 2016, just over 2 million people worldwide acquired HIV infection, mostly via heterosexual transmission and mostly in sub-Saharan Africa [1]. Antiretroviral treatment (ART) aims to suppress viral load to very low, or undetectable, levels, delaying HIV disease progression [2,3] and reducing the risk of onward transmission [4]. Following the 2015 WHO guidelines recommending ART for all HIV-positive people regardless of CD4 count, WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) issued the 90–90–90 target, aiming by 2020 to have 90% of infected people knowing their HIV status, 90% of HIV-positive people initiated on ART, and 90% of people treated with ART virally suppressed [5], so as to achieve containment of the HIV epidemic. We commend Richard Hayes and colleagues for their success in navigating the complex logistic challenges in implementing a large-scale universal testing and treatment (UTT) intervention in sub-Saharan Africa, as described in their accompanying research article in PLOS Medicine [6]. They report how close they were able to come to reaching the first two stages of the 90–90–90 target in four communities in Zambia after one year of implementing their PopART intervention (comprising home-based HIV testing by Community HIV care Providers [CHiPs] with support for linkage to care, adherence, and retention). Among those consenting to the intervention, 6,197 HIV-positive individuals not on ART (most of whom had never been in care) were referred to care, 42% of whom initiated ART within six months and 53% by 12 months. Extrapolating to the entire population, the estimated percentage of HIV-positive adults who knew their status increased from 52% to 78% (men) and from 56% to 87% (women); percentages of known HIV-positive people on ART increased from 54% to 74% (men) and from 53% to 73% (women). The overall estimated percentage of HIV-positive adults on ART was 61% after 1 y of intervention implementation, compared to the WHO/UNAIDS target of 81% (90% of 90%). We note that many process indicators in the study were based on self-report and, apparently, data from the CHiPs electronic capture system were not verified with clinic data. Further, in this setting, in which nearly 50% of all HIV-positive individuals were ART-naive because they were newly diagnosed, it is likely that most of the 20% of people who migrated out of the area never linked to care or commenced ART. This 20% of people, no longer resident in the PopART communities, was not included in the denominator for the post-CHiPs evaluation at 12 months on linkage to care and ART initiation, which could have resulted in an overestimate of the change observed following the CHiPs intervention. Hayes and colleagues’ findings thus confirm the high acceptability of home-based HIV testing, and a less-than-optimal linkage to care, with initiation of ART rates suggesting that those who do link to care are willing to start ART; there is a substantial proportion of people identified as HIV positive who do not (yet) link to care, can therefore not be initiated on ART, and who may continue to transmit HIV. The Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS) 12249 Treatment as Prevention (TasP) trial, also evaluating a UTT intervention in rural South Africa, recently reported that 92% of HIV-positive individuals knew their status, 49% of those people initiated ART, and 93% achieved virological suppression on ART [7]. Higher rates of ART initiation were reported from Uganda and Kenya in the Sustainable East Africa Research in Community Health (SEARCH) trial, another UTT intervention study, with 97% of HIV-positive individuals knowing their status, 93% on ART, and 90% virologically suppressed at the end of year two [8]. Similarly, estimates from the Botswana Combination Prevention Project (BCPP) trial, a UTT intervention implemented in Botswana, reported that, overall, 70% of all HIV-positive individuals were virologically suppressed, close to the UNAIDS target of 73% (90% of 90% of 90%), with 83% of HIV-positive individuals diagnosed and 87% on ART, of whom 97% achieved virological suppression [9]. The different approaches to the estimation of percentages in the HIV care cascade in these trials hinder direct comparison of results; hence, we agree with Hayes and colleagues that approaches for estimating proportions of people at different stages in the HIV cascade need to be harmonised. Hayes and colleagues report that it was challenging to find young men at home, again in line with experience elsewhere [10]. Slow linkage to care suggests that people will only attend facilities once they prioritise doing so, and this is especially pertinent before they are driven to do so by the development of HIV symptoms and signs. An earlier study in rural KwaZulu-Natal highlighted that linkage to care was significantly less likely in those who had never been in HIV care, students in education, and those further away from the clinic, while those who had positive experience of ART in friends or family were more likely to access the trial clinic [11]. Hayes and colleagues will address progress towards the third 90% target later in their trial, but evidence from other studies suggests that once people engage with ART care, they are likely to adhere, at least in the short term [7], and that early linkage to ART care is the main hurdle in the HIV care cascade. The big question remains whether, in the global heterosexually-driven HIV epidemic, UTT will ultimately reduce HIV incidence to levels sufficient for containment. Findings from the ANRS 12249 TasP trial in South Africa showed little impact on HIV incidence [7], likely due to the slow linkage to care. Hayes and colleagues, although suggesting success of UTT in the first round of trial implementation, do not provide information about sustainability of either HIV test offer uptake or ART adherence, issues which may be especially important in settings with high migration movements. Overall, these results would suggest that it is unlikely that the rather optimistic forecasts, based on statistical modelling [12], of an imminent end to the global HIV epidemic will be fulfilled. The current gloomy political environment, with uncertainty about the global will to continue to support the large-scale implementation of HIV treatment and care programmes worldwide [13], further adds to the already considerable challenges faced by public health programmes in many settings with a high HIV burden. Health care system requirements for a successful UTT programme are not negligible, even if a UTT approach is found to be cost-effective [14]. Substantial resources are needed to further scale up ART for all HIV-positive adults, and allocation of limited resources will need to be optimised on the basis of evidence of efficacy. Given extensive resource constraints, there may come a time to consider whether public programmes will need to focus on providing optimal health care and support for those people who engage with care at public facilities and who have thus indicated that they have prioritised access to health care in their lives.
  9 in total

1.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.

Authors:  Reuben M Granich; Charles F Gilks; Christopher Dye; Kevin M De Cock; Brian G Williams
Journal:  Lancet       Date:  2008-11-27       Impact factor: 79.321

2.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

3.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

4.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

Authors:  Christine Danel; Raoul Moh; Delphine Gabillard; Anani Badje; Jérôme Le Carrou; Timothée Ouassa; Eric Ouattara; Amani Anzian; Jean-Baptiste Ntakpé; Albert Minga; Gérard M Kouame; Franck Bouhoussou; Arlette Emieme; Antoine Kouamé; André Inwoley; Thomas-d'Aquin Toni; Hugues Ahiboh; Mathieu Kabran; Cyprien Rabe; Baba Sidibé; Gustave Nzunetu; Romuald Konan; Joachim Gnokoro; Patrice Gouesse; Eugène Messou; Lambert Dohoun; Synali Kamagate; Abo Yao; Solange Amon; Amadou-Barenson Kouame; Aboli Koua; Emmanuel Kouamé; Yao Ndri; Olivier Ba-Gomis; Marcelle Daligou; Simplice Ackoundzé; Denise Hawerlander; Alex Ani; Fassery Dembélé; Fatoumata Koné; Calixte Guéhi; Constance Kanga; Serge Koule; Jonas Séri; Mykayila Oyebi; Nathalie Mbakop; Olewole Makaila; Carole Babatunde; Nathanael Babatounde; Gisèle Bleoué; Mireille Tchoutedjem; Alain-Claude Kouadio; Ghislaine Sena; Sahinou-Yediga Yededji; Rodrigue Assi; Alima Bakayoko; Alassane Mahassadi; Alain Attia; Armel Oussou; Max Mobio; Doféré Bamba; Mesmin Koman; Apollinaire Horo; Nina Deschamps; Henri Chenal; Madeleine Sassan-Morokro; Seidou Konate; Kakou Aka; Eba Aoussi; Valérie Journot; Célestin Nchot; Sophie Karcher; Marie-Laure Chaix; Christine Rouzioux; Papa-Salif Sow; Christian Perronne; Pierre-Marie Girard; Hervé Menan; Emmanuel Bissagnene; Auguste Kadio; Virginie Ettiegne-Traore; Corinne Moh-Semdé; Abo Kouame; Jean-Marie Massumbuko; Geneviève Chêne; Mireille Dosso; Serge K Domoua; Thérèse N'Dri-Yoman; Roger Salamon; Serge P Eholié; Xavier Anglaret
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

5.  Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.

Authors:  Tendani Gaolathe; Kathleen E Wirth; Molly Pretorius Holme; Joseph Makhema; Sikhulile Moyo; Unoda Chakalisa; Etienne Kadima Yankinda; Quanhong Lei; Mompati Mmalane; Vlad Novitsky; Lillian Okui; Erik van Widenfelt; Kathleen M Powis; Nealia Khan; Kara Bennett; Hermann Bussmann; Scott Dryden-Peterson; Refeletswe Lebelonyane; Shenaaz El-Halabi; Lisa A Mills; Tafireyi Marukutira; Rui Wang; Eric J Tchetgen Tchetgen; Victor DeGruttola; M Essex; Shahin Lockman
Journal:  Lancet HIV       Date:  2016-03-24       Impact factor: 12.767

6.  Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints.

Authors:  Evelinn Mikkelsen; Jan A C Hontelez; Maarten P M Jansen; Till Bärnighausen; Katharina Hauck; Kjell A Johansson; Gesine Meyer-Rath; Mead Over; Sake J de Vlas; Gert J van der Wilt; Noor Tromp; Leon Bijlmakers; Rob M P M Baltussen
Journal:  PLoS Med       Date:  2017-02-21       Impact factor: 11.069

7.  A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.

Authors:  Richard Hayes; Sian Floyd; Ab Schaap; Kwame Shanaube; Peter Bock; Kalpana Sabapathy; Sam Griffith; Deborah Donnell; Estelle Piwowar-Manning; Wafaa El-Sadr; Nulda Beyers; Helen Ayles; Sarah Fidler
Journal:  PLoS Med       Date:  2017-05-02       Impact factor: 11.069

8.  Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South Africa.

Authors:  Mélanie Plazy; Kamal El Farouki; Collins Iwuji; Nonhlanhla Okesola; Joanna Orne-Gliemann; Joseph Larmarange; France Lert; Marie-Louise Newell; François Dabis; Rosemary Dray-Spira
Journal:  J Int AIDS Soc       Date:  2016-06-01       Impact factor: 5.396

9.  Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial.

Authors:  Collins C Iwuji; Joanna Orne-Gliemann; Joseph Larmarange; Nonhlanhla Okesola; Frank Tanser; Rodolphe Thiebaut; Claire Rekacewicz; Marie-Louise Newell; Francois Dabis
Journal:  PLoS Med       Date:  2016-08-09       Impact factor: 11.069

  9 in total
  5 in total

1.  HIV testing: the 'front door' to the UNAIDS 90-90-90 target.

Authors:  Collins Iwuji; Marie-Louise Newell
Journal:  Public Health Action       Date:  2017-06-21

Review 2.  Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials.

Authors:  Marie A Brault; Donna Spiegelman; Salim S Abdool Karim; Sten H Vermund
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

3.  Patterns and Gaps Identified in a Systematic Review of the Hepatitis C Virus Care Continuum in Studies among People Who Use Drugs.

Authors:  Ashly E Jordan; David C Perlman; Jennifer Reed; Daniel J Smith; Holly Hagan
Journal:  Front Public Health       Date:  2017-12-18

4.  Cost-effectiveness of HIV Prevention Interventions in Sub-Saharan Africa: A Systematic Review.

Authors:  Supriya Sarkar; Phaedra Corso; Shideh Ebrahim-Zadeh; Patricia Kim; Sana Charania; Kristin Wall
Journal:  EClinicalMedicine       Date:  2019-05-20

5.  Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.

Authors:  Marie A Brault; Donna Spiegelman; James Hargreaves; Denis Nash; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-01       Impact factor: 3.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.